Anemia in CKD PatientsNCT07334145
Effect of SGLT2 Inhibitors on Anemic CKD Patients
An observational study of Anemia in CKD Patients, run by Sohag University at 1 site in Egypt.
Trial summary
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Anemia in CKD Patients
- What is being tested?
- SGLT2 inhibitor
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2026to 1 Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: people in sohag twen
Who may be able to join
- age more than 18 years
- CKD stage 1_4
- baseline hemoglobin 8.5 to 12.9 g/dl
- stable anemia regimen for more than 8 weeks
Who cannot join
- dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Sohag University Hospital
Sohag, Sohag University
Romany Naguib Mikhaeil, Master, 01274426883, romanynaguib977@gmail.com
About this study
Official title: Effect of SGLT2 Inhibitors On Anemia in Patients With Chronic Kidney Disease (CKD)
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD
- Conditions
- Anemia in CKD Patients
- Being tested
- SGLT2 inhibitor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SGLT2 inhibitorDrug
prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1_4
| Study group | Role | What they receive |
|---|---|---|
| CKD patients stage 1_4 | Not described Receives: Drug: SGLT2 inhibitor |
What is being measured
The primary outcome is the main question the study is designed to answer.
hemoglobin level
use the hemoglobin level to assist the effect of SGLT2 inhibitors On anemia correction
Measured: 12 weeks
change in hemoglobin level
anemia correction
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start1 Jan 2026 (estimated)
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anemia in CKD PatientsStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Romany Nageb, Sohag University
- Investigators
- Romany Naguib Mikhaeil, master, Principal investigator, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07334145
- Sponsor's protocol ID
- soh_med__25_12_6MS
- Status last verified
- Jan 2026
- First submitted
- 31 Dec 2025
- Last updated
- 14 Jan 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of SGLT2 Inhibitors On Anemia in Patients With Chronic Kidney Disease (CKD)
- ClinicalTrials.gov ID
- NCT07334145
- Acronym / sponsor ID
- soh_med__25_12_6MS
- Conditions
- Anemia in CKD Patients
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 1 Sep 2026 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CKD patients stage 1_4 | – | Drug: SGLT2 inhibitor |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- people in sohag twen
Key inclusion criteria (4 listed)
- age more than 18 years
- CKD stage 1_4
- baseline hemoglobin 8.5 to 12.9 g/dl
- stable anemia regimen for more than 8 weeks
Key exclusion criteria (1 listed)
- dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SGLT2 inhibitorprescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1_4 | Drug | CKD patients stage 1_4 |
Primary outcome
hemoglobin level
Time frame: 12 weeks
use the hemoglobin level to assist the effect of SGLT2 inhibitors On anemia correction
change in hemoglobin level
Time frame: 12 weeks
anemia correction
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Anemia in CKD Patients
RecruitingObservational study
Nutritional Status in Patients With Chronic Kidney Disease Receiving 7.2% Amino Acids During Hemodialysis
Malnutitrion, Chronic Kidney Disease on Hemodialysis
RecruitingPhase 2
A Study of Luspatercept in People With Anemia
Anemia, Chronic Kidney Disease
Not yet recruitingObservational study
ESA Hyporesponsiveness in Hemodialysis Patients
Chronic Kidney Disease (CKD), Hemodialysis Complication
RecruitingPhase 2
Combination Therapy of Romiplostim and Erythropoiesis-stimulating Agents
Anemia Associated With Chronic Kidney Disease
Active, not recruitingObservational study
SGLT2 Inhibitors and Renal Anemia in Japan: RWD
Chronic Kidney Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Romany Naguib Mikhaeil, master principal investigator
Sohag University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anemia in CKD Patients, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Romany Naguib Mikhaeil, master (01274426883 ext. 01005823021, romanynaguib977@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
hemoglobin level (time frame: 12 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.